TZ Ref No.: TZ-1105251
Contract Award
Awarded Contract
National (NCB)
United States
Pharmaceuticals
Healthcare and Medicine
Chemicals
Advance the development of SCY-247, a novel antifungal currently in Phase 1 clinical trials, for the treatment of invasive candidiasis and prophylaxis of invasive fungal disease as oral and IC formula
Doc ref no.
75A50126C00007
Sector
Pharmaceuticals, Healthcare and Medicine, Chemicals
Contract Date
26 Sep 2026
Contract Value
$ 213.9M
Contract Intelligence
AI opportunity notes and scope analysis for this contract award
Opportunity Notes
A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.
Sign in to unlock Bid Fit & AI Opportunity Intelligence
TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).
Contract Description
Award Notice Advance the development of SCY-247, a novel antifungal currently in Phase 1 clinical trials, for the treatment of invasive candidiasis and prophylaxis of invasive fungal disease as oral and IC formula
Related Procurement Opportunities
Similar tenders in Pharmaceuticals, Healthcare and Medicine, Chemicals